AVTX Reports 42.2% HiSCR75 Response, 42.9% Response, Phase 2 LOTUS Trial Success, Advances to Phase 3 Program
Avalo Therapeutics, Inc. Common Stock · PHARMACEUTICAL PREPARATIONS · Now $15.75
+34% in 1d after detection
Post-detection moves
1h
—
1d
+34%
3d
+33%
7d
+17%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS